CD80 and non-small cell lung carcinoma: Autologous CAR-T cells targeting PD-L1 and CD80/CD86 are being used for the treatment of recurrent or refractory NSCLC in an early phase I study (NCT03060343) to determine safety, tolerance, and engraftment potential.